Patient Site Healthcare Professional Site
VIVITROL (naltrexone for extended-release injectable suspension) VIVITROL: A Treatment Option For The Daily Struggle Against Alcohol Dependence. One dose all month long.
Healthcare Professional Site
Prescribing Information
Send to a Friend
Homepage About Vivitrol Request Information SEARCH
About VIVITROL
My Path to Recovery
Overview


Mechanism of action


Efficacy


Dosage/Administration


Adherence


Safety Considerations


VIVITROL Preparation and Administration
What is VIP3?


How do I start a patient on therapy?

Overview

What is VIVITROL?

VIVITROL is naltrexone for extended-release injectable suspension. Naltrexone, the active ingredient in VIVITROL, is an opioid antagonist with highest affinity for the µ-opioid receptor shown to be effective in the treatment of alcohol dependence in conjunction with psychosocial support such as counseling.7

  • VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to treatment initiation. Patients should not be actively drinking at the time of initial VIVITROL administration. VIVITROL should be part of a comprehensive management program that includes psychosocial support. (see Dosage/Administration)7
  • VIVITROL uses a unique drug-delivery technology to provide a month of medication with just one dose (see Mechanism of action)7
  • VIVITROL is generally well tolerated, with low discontinuation rates due to adverse effects. (see Safety considerations)7
  • Patients should be warned of the risk of hepatic injury. VIVITROL does not appear to be a hepatotoxin at recommended doses. (see Safety considerations)7
Important Safety Information
Naltrexone has the capacity to cause hepatocellular injury when given in excessive doses. Naltrexone is contraindicated in acute hepatitis or liver failure, and its use in patients with active liver disease must be carefully considered in light of its hepatotoxic effects. The margin of separation between the apparently safe dose of naltrexone and the dose causing hepatic injury appears to be only five-fold or less. VIVITROL does not appear to be a hepatotoxin at the recommended doses. Patients should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms of acute hepatitis. Use of VIVITROL should be discontinued in the event of symptoms and/or signs of acute hepatitis.
VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL.

Patients should not be actively drinking at the time of initial VIVITROL administration.

Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support.